3-(4-氯苯基)-6-肼基哒嗪 | 60478-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-(4-氯苯基)-6-肼基哒嗪
• 英文名称: 3-(4-chloro-phenyl)-6-hydrazino-pyridazine
• 英文别名: 6-(p-chlorophenyl)-3-hydrazinopyridazine；6-(p-Chlorphenyl)-3-hydrazinopyridazin；3-(4-Chlorophenyl)-6-hydrazinopyridazine；[6-(4-chlorophenyl)pyridazin-3-yl]hydrazine
• CAS: 60478-25-3
• 化学式: C₁₀H₉ClN₄
• mdl: MFCD07389029
• 分子量: 220.661
• InChiKey: AZCTXHPEZWKVGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• WGK Germany：
  3

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-(4-Chlorophenyl)-6-Hydrazinopyridazine
: CBR01164
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 220,66 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3-(4-Chlorophenyl)-6-Hydrazinopyridazine
Acute Tox. 3; H301 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3-(4-Chlorophenyl)-6-Hydrazinopyridazine
T, R25 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (3-(4-Chlorophenyl)-6-Hydrazinopyridazine)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (3-(4-Chlorophenyl)-6-Hydrazinopyridazine)
IATA: Toxic solid, organic, n.o.s. (3-(4-Chlorophenyl)-6-Hydrazinopyridazine)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(4-氯苯基)-6-肼基哒嗪 在 镍 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.32 kPa 条件下， 生成 3-氨基-6-(4-氯苯基)哒嗪
  参考文献：
  名称：

  一系列作为选择性GABA-A拮抗剂的γ-氨基丁酸氨基哒嗪衍生物的合成与构效关系。

  摘要：

  我们最近发现，GABA的芳基氨基哒嗪衍生物SR 95103 [2-（3-羧丙基）-3-氨基-4-甲基-6-苯基吡啶并鎓氯化物]是一种选择性和竞争性的GABA-A受体拮抗剂。为了进一步探索对GABA受体亲和力的结构要求，我们通过将各种哒嗪结构连接到GABA或GABA样侧链上，合成了38种化合物。大多数化合物从大鼠脑膜中取代了[3H] GABA。所有活性化合物都拮抗了GABA引起的[3H]地西p结合的增强，强烈表明所有这些化合物都是GABA-A受体拮抗剂。从大鼠脑膜置换[3H] GABA的化合物均未与其他GABA识别位点（GABA-B受体，GABA吸收结合位点，谷氨酸脱羧酶，GABA转氨酶）相互作用。它们不与与GABA-A受体相关的Cl-离子载体相互作用，也不与苯并二氮杂str，士的宁和谷氨酸结合位点相互作用。因此，这些化合物似乎是特异性的GABA-A受体拮抗剂。就结构活性而言，可以得出结论，

  DOI：

  10.1021/jm00385a003
• 作为产物：
  描述：

  3-(4-氯苯甲酰)丙酸 在 sodium acetate 、 一水合肼 、 三氯氧磷 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 28.0h， 生成 3-(4-氯苯基)-6-肼基哒嗪
  参考文献：
  名称：

  Islam, Mojahidul; Siddiqui, Anees A., Acta poloniae pharmaceutica, 2010, vol. 67, # 5, p. 555 - 562

  摘要：

  DOI：

文献信息

• Synthesis, vasorelaxant activity and 2D-QSAR study of some novel pyridazine derivatives
  作者：Riham F. George、Dalia O. Saleh

  DOI：10.1016/j.ejmech.2015.12.015

  日期：2016.1

  Novel 3,6-disubstituted pyridazines were synthesized by facile method and screened for their vasorelaxant properties utilizing isolated thoracic rat aortic rings. Compounds 8a and 11a exerted potent vasorelaxant activity (IC50 = 198 and 177 μM, respectively) relative to doxazosin mesylate (used reference standard, IC50 = 226 μM), that, they may represent promising hits for treatment of cardiovascular

  通过简便的方法合成了新颖的3,6-二取代的哒嗪，并使用分离的大鼠胸主动脉环筛选了它们的血管舒张特性。 相对于甲磺酸多沙唑嗪（使用的参考标准，IC 50  = 226μM），化合物8a和11a发挥了强大的血管舒张活性（分别为IC 50 = 198和177μM），它们可能代表了治疗心血管疾病的有希望的药物。观察到的活性通过具有统计学意义的QSAR模型验证（N = 32，n = 6，R 2  = 0.811782，R 2 cvOO  = 0.7153，R 2 cvMO  = 0.7209，F = 17.9708，s 2  = 9.65226×10 -8）是使用CODESSA-Pro软件获得的。
• Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates
  申请人：American Cyanamid Company

  公开号：US04092311A1

  公开（公告）日：1978-05-30

  This disclosure describes novel alkyl 3-[6-(aryl)-3-pyridazinyl]-carbazates useful as hypotensive agents in mammals. SP CROSS REFERENCE TO RELATED APPLICATIONS This application is a continuation of our copending application Ser. No. 692,254, filed June 3, 1976 now abandoned, which in turn is a continuation-in-part of our abandoned application Ser. No. 552,024, filed Feb. 24, 1975 now abandoned.

  本公开描述了一种新的烷基3-[6-(芳基)-3-吡啶并嗪基]-氨基甲酸酯，可用作哺乳动物的降压剂。SP与相关申请的交叉引用 本申请是我们待决申请Ser. No. 692,254的延续申请，该待决申请于1976年6月3日提交，现已废弃，而该待决申请又是我们废弃申请Ser. No. 552,024的部分延续申请，该废弃申请于1975年2月24日提交，现已废弃。
• Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines
  作者：J. D. Albright、D. B. Moran、W. B. Wright、J. B. Collins、B. Beer、A. S. Lippa、E. N. Greenblatt

  DOI：10.1021/jm00137a020

  日期：1981.5

  The synthesis of a series of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines (VIII) is reported. Some of these derivatives show activity in tests predictive of anxiolytic activity [(a) protection against pentylenetetrazole-induced convulsions; (b) thirsty rat conflict procedure]. They also represent a new class of compound which inhibits [3H]diazepam binding. Structure--activity correlations

  报道了一系列6-（取代的苯基）-1，2，4-三唑并[4，3-b]哒嗪（VIII）的合成。这些衍生物中的一些在预测抗焦虑活性的试验中显示出活性[（a）防止戊四唑诱发的惊厥；（b）口渴的老鼠冲突程序]。它们也代表了抑制[3H]地西p结合的一类新化合物。讨论了结构-活性的相关性，以及结构VIII抑制[3H]地西ze结合的能力（体外）。
• ALBRIGHT, J. D.;MORAN, D. B.;WRIGHT, W. B. ,, JR.;COLLINS, J. B.;BEER, B.+, J. MED. CHEM., 1981, 24, N 5, 592-600
  作者：ALBRIGHT, J. D.、MORAN, D. B.、WRIGHT, W. B. ,, JR.、COLLINS, J. B.、BEER, B.+

  DOI：——

  日期：——
• US4092311A
  申请人：——

  公开号：US4092311A

  公开（公告）日：1978-05-30